{"id":249813,"date":"2023-08-25T00:00:00","date_gmt":"2023-08-25T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidmd0071-biopharma-renal-anemia-epidemiology-mature-markets-data\/"},"modified":"2026-03-31T10:32:21","modified_gmt":"2026-03-31T10:32:21","slug":"epidmd0071-biopharma-renal-anemia-epidemiology-mature-markets-data","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidmd0071-biopharma-renal-anemia-epidemiology-mature-markets-data\/","title":{"rendered":"Renal Anemia &#8211; Epidemiology &#8211; Mature markets data"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of renal anemia comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of renal anemia for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the major mature pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology&#8217;s renal anemia forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people diagnosed with renal anemia, how many in each country across the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of renal anemia over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MicroSoft Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 27 renal anemia patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Stage 1 <abbr title=\"chronic kidney disease\">CKD<\/abbr> with anemia (<abbr title=\"hemoglobin\">Hb<\/abbr> less than 13 g\/dl) prevalent cases<\/li>\n<li>Stage 2 <abbr title=\"chronic kidney disease\">CKD<\/abbr> with anemia (<abbr title=\"hemoglobin\">Hb<\/abbr> less than 13 g\/dl) prevalent cases<\/li>\n<li>Stage 3a <abbr title=\"chronic kidney disease\">CKD<\/abbr> with anemia (<abbr title=\"hemoglobin\">Hb<\/abbr> less than 13 g\/dl) prevalent cases<\/li>\n<li>Stage 3b <abbr title=\"chronic kidney disease\">CKD<\/abbr> with anemia (<abbr title=\"hemoglobin\">Hb<\/abbr> less than 13 g\/dl) prevalent cases<\/li>\n<li>Stage 4 <abbr title=\"chronic kidney disease\">CKD<\/abbr> with anemia (<abbr title=\"hemoglobin\">Hb<\/abbr> less than 13 g\/dl) prevalent cases<\/li>\n<li><abbr title=\"end-stage renal disease\">ESRD<\/abbr> <abbr title=\"chronic kidney disease\">CKD<\/abbr> with anemia (<abbr title=\"hemoglobin\">Hb<\/abbr> less than 13 g\/dl) prevalent cases<\/li>\n<li>Nondialysis <abbr data-abbreviation-entity=\"4765\" title=\"chronic kidney disease\">CKD<\/abbr> cases with anemia (<abbr title=\"hemoglobin\">Hb<\/abbr> less than 13 g\/dl) prevalent cases<\/li>\n<li>Dialysis <abbr title=\"chronic kidney disease\">CKD<\/abbr> cases with anemia (<abbr title=\"hemoglobin\">Hb<\/abbr> less than 13 g\/dl) prevalent cases<\/li>\n<li>Stage 1 <abbr title=\"chronic kidney disease\">CKD<\/abbr> with moderate anemia (<abbr title=\"hemoglobin\">Hb<\/abbr> 10-13 g\/dl) prevalent cases<\/li>\n<li>Stage 1 <abbr title=\"chronic kidney disease\">CKD<\/abbr> with severe anemia (<abbr title=\"hemoglobin\">Hb<\/abbr> less than 10 g\/dl) prevalent cases<\/li>\n<li>\u2026 and many more (details available on request).<\/li>\n<\/ul>\n<p>Note: coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-249813","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-renal-anemia","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249813","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249813\/revisions"}],"predecessor-version":[{"id":281405,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249813\/revisions\/281405"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}